Erratum to: Phase II Study of Gemcitabine and Erlotinib as Adjuvant Therapy for Patients with Resected Pancreatic Cancer

被引：0
|
作者：
Philip Q. Bao
Ramesh K. Ramanathan
Alyssa Krasinkas
Nathan Bahary
Barry C. Lembersky
David L. Bartlett
Steven J. Hughes
Kenneth K. Lee
A. James Moser
Herbert J. Zeh
机构：
[1] Stony Brook University Hospital,Department of Surgery
[2] Virginia G. Piper Cancer Center,Department of Pathology
[3] University of Pittsburgh Medical Center,Department of Medical Oncology
[4] University of Pittsburgh Medical Center,Department of Surgery, Division of Surgical Oncology
[5] University of Pittsburgh Medical Center,undefined
来源：
Annals of Surgical Oncology | 2011年 / 18卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：323 / 323
相关论文
共 50 条
  • [1] Phase II Study of Gemcitabine and Erlotinib as Adjuvant Therapy for Patients with Resected Pancreatic Cancer
    Bao, Philip Q.
    Ramanathan, Ramesh K.
    Krasinkas, Alyssa
    Bahary, Nathan
    Lembersky, Barry C.
    Bartlett, David L.
    Hughes, Steven J.
    Lee, Kenneth K.
    Moser, A. James
    Zeh, Herbert J., III
    ANNALS OF SURGICAL ONCOLOGY, 2011, 18 (04) : 1122 - 1129
  • [2] Phase II Study of Gemcitabine and Erlotinib as Adjuvant Therapy for Patients with Resected Pancreatic Cancer
    Philip Q. Bao
    Ramesh K. Ramanathan
    Alyssa Krasinkas
    Nathan Bahary
    Barry C. Lembersky
    David L. Bartlett
    Steven J. Hughes
    Kenneth K. Lee
    A. James Moser
    Herbert J. Zeh
    Annals of Surgical Oncology, 2011, 18 : 1122 - 1129
  • [3] Phase II Study of Gemcitabine and Erlotinib as Adjuvant Therapy for Patients with Resected Pancreatic Cancer (vol 18, pg 1122, 2011)
    Bao, Philip Q.
    Ramanathan, Ramesh K.
    Krasinkas, Alyssa
    Bahary, Nathan
    Lembersky, Barry C.
    Bartlett, David L.
    Hughes, Steven J.
    Lee, Kenneth K.
    Moser, A. James
    Zeh, Herbert J., III
    ANNALS OF SURGICAL ONCOLOGY, 2011, 18 : S323 - S323
  • [4] Adjuvant Gemcitabine and Erlotinib for Resected Pancreatic Cancer
    Bao, P.
    Ramanathan, R. K.
    Moser, A. J.
    Bahary, N.
    Lembersky, B. C.
    Bartlett, D. L.
    Hughes, S. J.
    Lee, K. K.
    Zeh, H. J.
    ANNALS OF SURGICAL ONCOLOGY, 2010, 17 : S66 - S66
  • [5] Adjuvant gemcitabine and concurrent radiation for patients with resected pancreatic cancer: a phase II study
    A W Blackstock
    F Mornex
    C Partensky
    L Descos
    L D Case
    S A Melin
    E A Levine
    G Mishra
    S A Limentani
    L A Kachnic
    J E Tepper
    British Journal of Cancer, 2006, 95 : 260 - 265
  • [6] Adjuvant gemcitabine and concurrent radiation for patients with resected pancreatic cancer: a phase II study
    Blackstock, A. W.
    Mornex, F.
    Partensky, C.
    Descos, L.
    Case, L. D.
    Melin, S. A.
    Levine, E. A.
    Mishra, G.
    Limentani, S. A.
    Kachnic, L. A.
    Tepper, J. E.
    BRITISH JOURNAL OF CANCER, 2006, 95 (03) : 260 - 265
  • [7] Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer
    Okusaka, Takuji
    Furuse, Junji
    Funakoshi, Akihiro
    Ioka, Tatsuya
    Yamao, Kenji
    Ohkawa, Shinichi
    Boku, Narikazu
    Komatsu, Yoshito
    Nakamori, Shoji
    Iguchi, Haruo
    Ito, Tetsuhide
    Nakagawa, Kazuhiko
    Nakachi, Kohei
    CANCER SCIENCE, 2011, 102 (02) : 425 - 431
  • [8] A phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer
    Nakachi, K.
    Okusaka, T. O.
    Funakoshi, A. F.
    Ioka, T. I.
    Yamao, K. Y.
    Ohkawa, S. O.
    Boku, N. B.
    Komatsu, Y. K.
    Nakamori, S. N.
    Furuse, J. F.
    EJC SUPPLEMENTS, 2009, 7 (02): : 387 - 387
  • [9] A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer
    Bassel Fuad El-Rayes
    Philip A. Philip
    Fazlul H. Sarkar
    Anthony F. Shields
    Ann Marie Ferris
    Kenneth Hess
    Ahmad O. Kaseb
    Milind M. Javle
    Gauri R. Varadhachary
    Robert A. Wolff
    James L. Abbruzzese
    Investigational New Drugs, 2011, 29 : 694 - 699
  • [10] A phase II study of erlotinib in gemcitabine refractory advanced pancreatic cancer
    Renouf, D. J.
    Tang, P. A.
    Hedley, D.
    Chen, E.
    Kamel-Reid, S.
    Tsao, M. S.
    Tran-Thanh, D.
    Gill, S.
    Dhani, N.
    Au, H. J.
    Wang, L.
    Moore, M. J.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 (11) : 1909 - 1915
12345